Validation of the RSClin risk calculator in the National Cancer Data Base

Abstract

AbstractBackgroundGuidelines recommend the use of genomic assays such as OncotypeDx to aid in decisions regarding the use of chemotherapy for hormone receptor–positive, HER2‐negative (HR+/HER2−) breast cancer. The RSClin prognostic tool integrates OncotypeDx and clinicopathologic features to predict distant recurrence and chemotherapy benefit, but further validation is needed before broad clinical adoption.MethodsThis study included patients from the National Cancer Data Base (NCDB) who were diagnosed with stage I–III HR+/HER2− breast cancer from 2010 to 2020 and received adjuvant endocrine therapy with or without chemotherapy. RSClin‐predicted chemotherapy benefit was stratified into low (<3% reduction in distant recurrence), intermediate (3%–5%), and high (>5%). Cox models were used to model mortality adjusted for age, comorbidity index, insurance, and race/ethnicity.ResultsA total of 285,441 patients were identified for inclusion from the NCDB, with an average age of 60 years and a median follow‐up of 58 months. Chemotherapy was associated with improved overall survival only for those predicted to have intermediate (adjusted hazard ratio [aHR], 0.68; 95% confidence interval [CI], 0.60–0.79) and high benefit per RSClin (aHR, 0.66; 95% CI, 0.61–0.72). Consistent benefit was seen in the subset with a low OncotypeDx score (<26) and intermediate (aHR, 0.66; 95% CI, 0.53–0.82) or high (aHR, 0.71; 95% CI, 0.58–0.86) RSClin‐predicted benefit. No survival benefit with chemotherapy was seen in patients with a high OncotypeDx score (≥26) and low benefit per RSClin (aHR, 1.70; 95% CI, 0.41–6.99).ConclusionsRSClin may identify high‐risk patients who benefit from treatment intensification more accurately than OncotypeDx, and further prospective study is needed.